CMR Surgical Robotics Raises $600M Funding

CMR Surgical Secures $600 Million in Series D Funding

CMR Surgical, a robotics firm headquartered in the United Kingdom, has announced the completion of a $600 million Series D funding round this morning. This new investment, spearheaded by SoftBank’s Vision Fund 2 and co-led by Ally Bridge Group, supplements the $384.8 million previously secured by the Cambridge-based company.

The financing brings the company’s valuation to $3 billion.

Versius Robotic System and its Applications

Versius represents CMR’s primary offering. This robotic system is engineered for minimally invasive surgical procedures, specifically targeting complex health issues such as bowel disease and bowel cancer. To date, the platform has facilitated over 1,000 surgical interventions globally, as reported by CMR.

The system’s design emphasizes accessibility and portability.

Global Adoption and Pandemic-Related Demand

Currently, four hospitals within the U.K.’s National Health Service (NHS) are utilizing the Versius surgical platform. Furthermore, adoption extends to numerous medical facilities across Europe, India, the Middle East, and Australia.

CMR highlights that the COVID-19 pandemic has created a substantial backlog of necessary surgical procedures, increasing demand for efficient surgical solutions.

Accessibility and Future Expansion

A key advantage of Versius, similar to other robotic surgical systems, lies in its potential to broaden access to advanced surgical techniques. Its modular construction and portability distinguish it from many competing systems, enhancing its accessibility.

The company intends to utilize the newly acquired funding to expedite the global deployment of the Versius platform.

CEO Statement and Investment Significance

“This latest financing equips CMR with significant funds to accelerate our mission of bringing Versius to hospitals worldwide, whilst providing full flexibility to achieve our goals,” stated Per Vegard Nerseth, CEO of CMR Surgical, in a press release.

He further noted that the $3 billion valuation reflects strong market interest in the product and the company’s overall scale, enabling further technological advancements and global expansion.

Trends in Surgical Robotics Investment

Investment in surgical robotics has been steadily increasing among venture capital firms. Recent funding rounds include $96 million for Memic, $10 million for ForSight, and $15 million for Activ.

However, CMR Surgical’s $600 million round stands out as a particularly substantial investment within this rapidly growing sector.